Ribavirin
Small molecule targets EIF4E
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Rebetol | — | 2023-10-18 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | COPEGUS | — | 2005-02-25 – 2011-08-22 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | REBETOL | — | 1998-12-09 – 2002-03-06 | fda.gov ↗ |
| Approved | EU (EMA) | Rebetol | — | 1999-05-06 | europa.eu ↗ |
| Label expansion | US (FDA) | VIRAZOLE | — | 1993-02-05 | fda.gov ↗ |
| Approved | US (FDA) | VIRAZOLE | — | 1985-12-31 | fda.gov ↗ |
Trials 434 · started per year
Also used as a comparator or background therapy in 341 trials
Press releases naming this drug 20 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-04-20 | AbbVie | AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2017-01-09 | AbbVie | Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients abbvie.com ↗ |
| 2016-04-25 | AbbVie | AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2016-04-16 | AbbVie | AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6 abbvie.com ↗ |
| 2016-02-26 | AbbVie | AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in abbvie.com ↗ |
| 2016-01-07 | AbbVie | FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2012-11-10 | Gilead Sciences | Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients gilead.com ↗ |
| 2012-04-19 | Gilead Sciences | Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients gilead.com ↗ |
| 2012-04-19 | Gilead Sciences | Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Na ïve Hepatitis C Patients gilead.com ↗ |
| 2012-04-19 | Gilead Sciences | Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients gilead.com ↗ |
| 2012-02-23 | Vertex Pharmaceuticals Incorporated | Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C vrtx.com ↗ |
| 2011-09-04 | Gilead Sciences | Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent gilead.com ↗ |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C vrtx.com ↗ |
| 2008-04-24 | Vertex Pharmaceuticals Incorporated | Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment vrtx.com ↗ |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗ |
| 2005-12-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval Of Ribavirin Tablets tevapharm.com ↗ |
| 2005-09-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Ribavirin Tablets tevapharm.com ↗ |
| 2004-10-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Ribavirin Capsules tevapharm.com ↗ |
| 2003-07-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces District Court Grants Motion for Summary Judgment of Non-Infringement of All Ribapharm Patents Related to Rebetol® tevapharm.com ↗ |
| 2003-03-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Schering-Plough Enter into License Agreement Covering Schering-Plough's Ribavirin Patents tevapharm.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 809 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ribavirin | “This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for...” NCT01908335 ↗758“The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose...” NCT02536313 ↗ “The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for...” NCT02300103 ↗ “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ “Day 1 (First 24 hours): IV Ribavirin (33mg/kg) loading dose followed by IV Ribavirin 16mg/kg every 6 hours Day 2 (24-48 hours): IV Ribavirin 16mg/kg four times daily (QDS) Days...” NCT06860334 ↗ “This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA)...” NCT01903278 ↗ “The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without...” NCT02487030 ↗ “Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus...” NCT01625793 ↗ “AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and...” PMID 27062488 ↗ Jun 2016 “We conducted a clinical trial using the DAA sofosbuvir plus ribavirin (SOF/RBV) and performed detailed mRNA expression analysis in liver and peripheral blood from patients who...” PMID 24983321 ↗ Jul 2014 “We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed...” PMID 27225242 ↗ May 2016 “Patients received a combination of ritonavir-boosted danoprevir (100 mg/100 mg) twice a day plus subcutaneous injection of weekly pegylated-interferon α-2a (180 μg) and oral...” PMID 31608213 ↗ Jul 2019 “intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for...” NCT00249574 ↗ “This study will evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) in participants with advanced liver disease or posttransplant and...” NCT01938430 ↗ “This study will evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) in participants with advanced liver disease or posttransplant and...” NCT02010255 ↗ “Eighty-three patients infected with HCV genotype 1 who were nonresponsive to standard therapy received pegylated IFN-α2a (360 μg once per week or 180 μg twice per week) with...” PMID 21439960 ↗ Mar 2011 “patients received sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination) plus GS-9857 (100 mg) once daily for 6-12 weeks, plus ribavirin for 1 treatment group...” PMID 27486034 ↗ Jul 2016 “Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution...” NCT02895958 ↗ “Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With...” NCT00446134 ↗ “Patients who fail to achieve sustained virological response (SVR) after treatment with sofosbuvir (SOF) plus ribavirin (RBV) with or without pegylated interferon (Peg-IFN) do...” PMID 25846014 ↗ Apr 2015 “This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated...” NCT01687257 ↗ “Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per...” NCT03146741 ↗ “An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due...” NCT04551768 ↗ “An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due...” NCT04356677 ↗ “Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =\>75 kg) daily in two divided doses” NCT03483987 ↗ “The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV)” NCT01909804 ↗ “Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01826981 ↗ “Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01682720 ↗ “Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).” NCT01188772 ↗ “Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).” NCT01054729 ↗ “All patients will complete an initial 4 weeks of treatment with HDV-Interferon (HDV-IFN) (treatment naïve by oral route and non-responders by SC route respectively) and ribavirin.” NCT00703872 ↗ “Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).” NCT01604850 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02120300 ↗ “This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.” NCT04387526 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01768286 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02201901 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01851330 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01713283 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01641640 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01384383 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01783678 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01565889 ↗ “Patients received peginterferon-α-2b (1.5 µg/kg/wk) plus ribavirin (400 to 1200 mg/d administered using a dose-escalating regimen and according to body weight) for 48 weeks.” PMID 22739223 ↗ Sep 2012 “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02021643 ↗ “Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan” NCT01910636 ↗ “In part B, patients with genotype 1 or 2 HCV infection were randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks.” PMID 26551051 ↗ Nov 2015 “Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment naïve patients with chronic hepatitis C (CHC).” NCT00188240 ↗ “A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model.” PMID 23264438 ↗ Dec 2012 “Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day” NCT02098616 ↗ “Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.” NCT00132210 ↗ “Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.” NCT01371604 ↗ “SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)” NCT01335711 ↗ “PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.” NCT00077636 ↗ “This study is to determine the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) with and without ribavirin (RBV)” NCT01965535 ↗ “BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rates of response to treatment with sofosbuvir and ribavirin.” PMID 28137593 ↗ Jan 2017 “Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).” NCT01743521 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01896193 ↗ “Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.” NCT04653818 ↗ “A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin” NCT02600351 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01984294 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01435044 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01667731 ↗ “We studied 15 patients chronically infected with genotype 1 HCV treated with telaprevir (TVR)/pegylated-interferon alpha/ribavirin.” PMID 24811404 ↗ Jul 2014 “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT02128542 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01329978 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01808248 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT02482077 ↗ “Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)” NCT04387539 ↗ “faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection.” PMID 27049487 ↗ May 2016 “plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses” NCT01273948 ↗ “Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)” NCT00977054 ↗ “Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients” NCT04391985 ↗ “Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.” PMID 23428875 ↗ Feb 2013 “Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day” NCT00532701 ↗ “53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks.” NCT03133065 ↗ “Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.” PMID 25710287 ↗ Mar 2015 “Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection” NCT02175758 ↗ “Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations” NCT01542788 ↗ “Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02583685 ↗ “All patients were treated with ledipasvir-sofosbuvir (90 mg and 400 mg) plus weight-based ribavirin for 12 weeks.” PMID 28535298 ↗ Jul 2017 “treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks” NCT02994056 ↗ “Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks” NCT00629967 ↗ “Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session ).” NCT03067883 ↗ “Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight” NCT02249182 ↗ “sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants” NCT04382339 ↗ “Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.” NCT00996216 ↗ “LT recipients with HCV were randomized to peginterferon alfa-2a/ribavirin treatment or observation.” PMID 21506241 ↗ May 2011 “ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)” NCT01271790 ↗ “PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)” NCT00530972 ↗ “in combination with weight dosed ribavirin daily administered orally in two divided doses” NCT01010646 ↗ “Patients in both groups will be treated with conventional interferon alfa and Ribavirin.” NCT01770483 ↗ “ribavirin (RBV) (1000 or 1200 mg per day orally depending on weight in 2 divided doses)” NCT01582035 ↗ “ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks” NCT00842205 ↗ “Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose” NCT01497366 ↗ “sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV)” NCT02822794 ↗ “Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h” NCT00979251 ↗ “Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution.” NCT04283513 ↗ “Ribavirin (RBV) was administered as a tablet orally according to body weight” NCT02480686 ↗ “Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30” NCT03702218 ↗ “asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks” NCT01888900 ↗ “pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV)” PMID 28282271 ↗ Feb 2017 “Ribavirin (RBV) capsules administered orally in a divided daily dose” NCT01260350 ↗ “Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules” NCT00135798 ↗ “Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin” NCT01683786 ↗ “sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV)” NCT01625338 ↗ “Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks” NCT00277238 ↗ “INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg” NCT01463592 ↗ “twice-daily oral ribavirin (600 to 1000mg/day) or placebo” NCT00144469 ↗ “plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day” NCT00491244 ↗ “Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)” NCT02673489 ↗ “sofosbuvir plus weight-based ribavirin (132 patients)” PMID 26575258 ↗ Nov 2015 “Sofosbuvir and Ledipasvir with weight based Ribavirin” NCT03481036 ↗ “Western Medicine：Ribavirin 10-15mg per kg every time” NCT01973855 ↗ “sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks” NCT01958281 ↗ “Ribavirin (RBV) 200 mg tablets administered orally” NCT01838590 ↗ “Pegylated Interferon (PegIFN) and ribavirin (RBV)” NCT01330316 ↗ “ledipasvir-sofosbuvir plus ribavirin for 12 weeks” PMID 24725239 ↗ Apr 2014 “140 mg of Ribavirin, administered every two weeks” NCT06034691 ↗ “Ribavirin/Nitazoxanide (RBV/NTZ) administered” NCT04563208 ↗ “SOF/VEL FDC and ribavirin (RBV) for 12 weeks” NCT02781558 ↗ “Infergen 15mcg/ d Avandia qd Ribavirin bid” NCT00207402 ↗ “weight-adjusted ribavirin po for 48 weeks.” NCT01529073 ↗ “Ribavirin, oral, 800-1400mg, daily, 12wks” NCT00142103 ↗ “ribavirin (RBV) combination therapy” NCT02060058 ↗ “sofosbuvir (SOF) + ribavirin (RBV)” NCT02738333 ↗ “sofosbuvir (SOF) + ribavirin (RBV)” NCT02201953 ↗ “with or without ribavirin (RBV)” NCT01726517 ↗ “with or without ribavirin (RBV)” NCT02472886 ↗ “with or without ribavirin (RBV)” NCT01975675 ↗ “REBETOL (ribavirin; SCH 18908)” NCT00039871 ↗ “Rebetol (ribavirin; SCH 18908)” NCT00811967 ↗ “Sofosbuvir + Ribavirin” NCT02469012 ↗ “Ribavirin (Copegus)” NCT01265511 ↗ “COPEGUS (Ribavirin)” NCT01033448 ↗ “Ribavirin tablets” NCT02247401 ↗ “Ribavirin 200 mg” NCT03365635 ↗ “Drug: Ribavirin” NCT00056862 ↗ “Drug: Ribavirin” NCT01332955 ↗ “Ribavirin (RBV)” NCT01962441 ↗ “Drug: Ribavirin” NCT02168361 ↗ “ribavirin” NCT00993122 ↗ |
| Known as | (b) SCH 18908, PEGETRON (ribavirin) Capsules | “(b) SCH 18908, PEGETRON® (ribavirin) Capsules” NCT00423800 ↗ |
| Known as | Copegus | “Pegylated interferon plus ribavirin is the standard first-line treatment in patients with chronic hepatitis C virus (HCV) mono-infection. Although the optimal anti-HCV regimen...” PMID 15563253 ↗ 200452“A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group...” NCT00535847 ↗ “A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and...” NCT00983853 ↗ “Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.” NCT00107653 ↗ “PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.” NCT00077636 ↗ “RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration.” NCT02340962 ↗ “Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day” NCT00532701 ↗ “Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID” NCT01435226 ↗ “Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol)” NCT00528528 ↗ “PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin)” NCT00087646 ↗ “GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.” NCT01353248 ↗ “PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)” NCT00707850 ↗ “PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)” NCT00707772 ↗ “ribavirin (CopegusTM, Roche) 1000-1200 mg QD combination therapy” NCT00433069 ↗ “Ribavirin (RBV, Copegus®) in people with genotype 1 hepatitis C” NCT00420784 ↗ “PegIFNα-2a (Pegasys) and Ribavirin (Copegus) triple therapy” NCT01479868 ↗ “COPEGUS is the Hoffman-La Roche brand name for ribavirin.” NCT00081770 ↗ “plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day” NCT00491244 ↗ “Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)” NCT01447420 ↗ “RBV (Copegus, Roche, Europe) based on body weight” NCT04382339 ↗ “ribavirin (Copegus, F. Hoffman-LaRoche)” NCT00491179 ↗ “Ribavirin (Copegus®) 1600 mg/day” NCT00470210 ↗ “Drug: ribavirin [Copegus]” NCT01628094 ↗ “Drug: ribavirin [Copegus]” NCT01278134 ↗ “Ribavirin (Copegus®)” NCT00088504 ↗ “Ribavirin (Copegus®)” NCT00262483 ↗ “Ribavirin (Copegus®)” NCT00372385 ↗ “ribavirin (Copegus]” NCT01591460 ↗ “Ribavirin (Copegus)” NCT01054573 ↗ “Ribavirin (Copegus)” NCT00910975 ↗ “ribavirin (COPEGUS)” NCT00909129 ↗ “ribavirin [Copegus]” NCT01585324 ↗ “ribavirin [Copegus]” NCT01749150 ↗ “Ribavirin (Copegus)” NCT01030432 ↗ “ribavirin [Copegus]” NCT00077649 ↗ “Ribavirin [Copegus]” NCT01057667 ↗ “ribavirin [Copegus]” NCT01903954 ↗ “COPEGUS (Ribavirin)” NCT01033448 ↗ “Copegus (ribavirin)” NCT01615393 ↗ “ribavirin [Copegus]” NCT01579019 ↗ “ribavirin [Copegus]” NCT01296971 ↗ “Copegus (ribavirin)” NCT00940420 ↗ |
| Known as | COPEGUS (RIBAVIRIN) | “COPEGUS (RIBAVIRIN)” NCT00909129 ↗ |
| Known as | RBV | “This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for...” NCT01908335 ↗191“This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to...” NCT00378599 ↗ “The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for...” NCT02300103 ↗ “The purpose of this study is to determine the effectiveness, safety and tolerability of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated...” NCT01498068 ↗ “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ “The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin...” NCT01370642 ↗ “The proposed study will quantify hepatic improvement and antiviral efficacy of the open-label interferon-free combination of 12 weeks of simeprevir (SMV, Simeprevir),...” NCT02455167 ↗ “METHODS: A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was undertaken in HIV-HCV-coinfected...” PMID 27845298 ↗ Nov 2016 “This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin...” NCT01500772 ↗ “Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the present phase II study was to examine virologic...” PMID 22473713 ↗ Jul 2012 “This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA)...” NCT01903278 ↗ “This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African...” NCT01446250 ↗ “The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with...” PMID 23907700 ↗ Oct 2013 “The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without...” NCT02487030 ↗ “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared With GS-5885, GS-9451 With Tegobuvir or RBV in...” NCT01435226 ↗ “Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC)...” PMID 19852040 ↗ Dec 2009 “The study aimed to determine if weight-based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its...” PMID 20721883 ↗ Oct 2010 “This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) plus ribavirin (RBV) in...” NCT02413593 ↗ “We conducted a clinical trial using the DAA sofosbuvir plus ribavirin (SOF/RBV) and performed detailed mRNA expression analysis in liver and peripheral blood from patients who...” PMID 24983321 ↗ Jul 2014 “This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV), pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with...” NCT00051077 ↗ “The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1...” NCT01849562 ↗ “Participants who experience confirmed post-treatment virologic failure (relapse) at or before Posttreatment Week 24 may be eligible to be enrolled in the Retreatment Substudy...” NCT02073656 ↗ “This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated...” NCT01687257 ↗ “We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for...” PMID 29091342 ↗ Dec 2017 “weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the...” NCT03250910 ↗ “The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants...” PMID 29473975 ↗ Apr 2018 “sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic genotype (GT) 1, 2, 3, 4, 5, or 6 hepatitis C virus (HCV) infection.” NCT01858766 ↗ “The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV)” NCT01909804 ↗ “Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01826981 ↗ “Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01682720 ↗ “Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).” NCT01054729 ↗ “Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).” NCT01188772 ↗ “Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).” NCT01604850 ↗ “Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4” NCT01241760 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01851330 ↗ “The usual treatment for HCV in people who are not HIV-infected is interferon-alfa (IFN) with ribavirin (RBV), an approved treatment by the Food and Drug Administration (FDA).” NCT00015652 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02201901 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01768286 ↗ “This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.” NCT04387526 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02021643 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01641640 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01565889 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01713283 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01384383 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01783678 ↗ “Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan” NCT01910636 ↗ “A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model.” PMID 23264438 ↗ Dec 2012 “ABT-333 (also known as dasabuvir) and ribavirin (RBV) in treatment-naïve and non responder participants with genotype 1 chronic hepatitis C virus (HCV) infection.” NCT01306617 ↗ “In hepatitis C virus (HCV)-infected patients receiving pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy, anemia is a well-known side effect.” PMID 15667486 ↗ Feb 2005 “Any GT that meets virologic futility criteria will be given the option of extending treatment with uprifosbuvir + RZR to 16 weeks with ribavirin (RBV) added.” NCT02956629 ↗ “PEGASYS® (peginterferon alfa-2a, PegIFN) plus standard-dose of ribavirin (RBV) in hepatitis C virus (HCV) genotype 1 infected, treatment-naïve CHC patients” NCT01937728 ↗ “To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses.” NCT00001015 ↗ “Currently, combination therapy with peginterferon (Peg-IFN) and ribavirin (RBV) has become the standard of care for chronic hepatitis C (CHC) patients” NCT00977054 ↗ “Based on ribavirin (RBV) monotherapy data, we hypothesized that RBV could improve virological responses when used in combination with tenofovir.” PMID 36586101 ↗ Dec 2022 “in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight” NCT00956982 ↗ “Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).” NCT01743521 ↗ “RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration.” NCT02340962 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT01896193 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01808248 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01329978 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT02482077 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT02128542 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01667731 ↗ “Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations” NCT01435044 ↗ “Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)” NCT04387539 ↗ “faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection.” PMID 27049487 ↗ May 2016 “triple therapy with Pegylated interferon alfa(PEG)/Ribavirin(RBV)/Boceprevir(BOC) treatment before liver transplantation(LT)” NCT02160080 ↗ “Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) are approved to treat HCV genotype 4 (GT4) infection.” NCT04378608 ↗ “followed by 26 days of ABT-333 or placebo with pegylated interferon a-2a (pegIFN) and ribavirin (RBV) combination therapy.” NCT00851890 ↗ “pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy.” PMID 26733671 ↗ Jan 2016 “We assessed the safety and efficacy of PegIFNα-2a and ribavirin (RBV) combination therapy in HCV-infected RT recipients.” PMID 23428875 ↗ Feb 2013 “Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations” NCT01542788 ↗ “HCV therapy with simeprevir, pegylated interferon alfa (PegIFNα) and ribavirin (RBV) have been shown to be superior” PMID 26753774 ↗ Jan 2016 “Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)” NCT02583685 ↗ “treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks” NCT02994056 ↗ “Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight” NCT02249182 ↗ “sofosbuvir (SOF)/velpatasvir (VEL) ± ribavirin (RBV), glecaprevir/pibrentasvir and SOF/VEL/voxilaprevir (VOX)” NCT05467826 ↗ “RBV is a nucleoside analog with structural similarities to guanosine, which modulates RNA and DNA synthesis.” NCT00944684 ↗ “High ribavirin (RBV) exposure is crucial to maximize the response to hepatitis C therapy in this population” PMID 20377423 ↗ Apr 2010 “Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV)” NCT02292719 ↗ “Consensus Interferon-Alpha (CIFN) Plus Interferon Gamma-1b (IFN-γ 1b) With or Without Ribavirin (RBV)” NCT00084279 ↗ “sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants” NCT04382339 ↗ “with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day)” NCT02442271 ↗ “Sofosbuvir (SOF) and ribavirin (RBV) will be taken orally once daily for the entire study period.” NCT02541409 ↗ “Patients with cirrhosis and genotype (G2) were treated with SOF+DCV+ribavirin (RBV) for 12 weeks” PMID 30211847 ↗ Jan 2019 “Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening” NCT02483156 ↗ “treatment with ribavirin (RBV) plus isoprinosine (INPX) in preventing the development of AIDS” NCT00000699 ↗ “standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a), Ribavirin (RBV) and Amantadine (AMA)” NCT00299923 ↗ “pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV)” PMID 17894323 ↗ Oct 2007 “800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients” PMID 27782373 ↗ Dec 2016 “Standard treatment, pegylated-interferon (IFN) alfa and ribavirin (RBV), has an efficacy” NCT01185028 ↗ “ribavirin (RBV) (1000 or 1200 mg per day orally depending on weight in 2 divided doses)” NCT01582035 ↗ “standard or pegylated interferon alfa \[PEG-IFN\] in combination with ribavirin \[RBV\]” NCT00315432 ↗ “plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day)” NCT01716585 ↗ “Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose” NCT01497366 ↗ “peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) for difficult-to-treat patients” PMID 22239511 ↗ Nov 2011 “Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)” NCT03710252 ↗ “sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV)” NCT02822794 ↗ “Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV)” NCT01938625 ↗ “ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks” NCT01939197 ↗ “Ribavirin (RBV) was administered as a tablet orally according to body weight” NCT02480686 ↗ “peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy” NCT00687544 ↗ “pegylated interferon (IFN) alfa-2b in combination with ribavirin (RBV)” NCT00117533 ↗ “Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)” NCT00423800 ↗ “Ribavirin (RBV) capsules administered orally in a divided daily dose” NCT01260350 ↗ “Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules” NCT00135798 ↗ “Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks” NCT01455090 ↗ “pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV)” PMID 22885330 ↗ Aug 2012 “sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV)” NCT01625338 ↗ “Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV)” NCT01606800 ↗ “Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV)” PMID 20189674 ↗ Feb 2010 “ribavirin (RBV), for Japanese difficult-to-treat patients” PMID 25196718 ↗ Nov 2014 “Co-administered With Ribavirin (RBV) for 12 or 16 Weeks” NCT02023112 ↗ “Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)” NCT03020004 ↗ “Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)” NCT02673489 ↗ “group 1: sofosbuvir (SOF)+ribavirin (RBV) for 24 weeks” PMID 29727383 ↗ Aug 2018 “Ribavirin (RBV) 200 mg tablets administered orally” NCT01838590 ↗ “sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks” NCT01958281 ↗ “Randomised PegIFN alfa 2b + ribavirin (RBV) arm” NCT00323804 ↗ “ARM 1: PEG-IFN and weight-based ribavirin (RBV)” NCT02006745 ↗ “fixed dose combination (FDC) ± ribavirin (RBV)” NCT02378935 ↗ “pegylated interferon alfa and ribavirin (RBV)” PMID 21221804 ↗ Jan 2011 “Pegylated-Interferon-alfa-2a /ribavirin (RBV)” NCT01513941 ↗ “Ribavirin/Nitazoxanide (RBV/NTZ) administered” NCT04563208 ↗ “Arm 1A: PegIntron (PEG) + Ribavirin (RBV)” NCT00160251 ↗ “ribavirin (RBV) combination therapy” NCT02060058 ↗ “sofosbuvir (SOF) + ribavirin (RBV)” NCT02201953 ↗ “ribavirin (RBV) orally twice daily” NCT00372385 ↗ “plus Ribavirin (RBV) for 12 weeks” NCT02247401 ↗ “with and without ribavirin (RBV)” NCT01767116 ↗ “with and without Ribavirin (RBV)” NCT02613403 ↗ “with or without ribavirin (RBV)” NCT02472886 ↗ “with or without ribavirin (RBV)” NCT01975675 ↗ “with or without RBV (ribavirin)” NCT02461745 ↗ “Drug: Ribavirin (RBV) tablet” NCT00528528 ↗ “Drug: Ribavirin (RBV)” NCT01846832 ↗ “Drug: Ribavirin (RBV)” NCT02216422 ↗ “plus ribavirin (RBV)” NCT01854528 ↗ “ribavirin (RBV).” NCT01194037 ↗ “Ribavirin (RBV)” NCT01704755 ↗ “ribavirin (RBV)” NCT01468584 ↗ “Ribavirin (RBV)” NCT01281839 ↗ “ribavirin (RBV)” NCT01054573 ↗ “Ribavirin (RBV)” NCT01609933 ↗ “Ribavirin (RBV)” NCT01440595 ↗ “Ribavirin (RBV)” NCT01011166 ↗ “Ribavirin (RBV)” NCT02167945 ↗ “ribavirin (RBV)” NCT02446717 ↗ “Ribavirin (RBV)” NCT01962441 ↗ “Ribavirin (RBV)” NCT00704405 ↗ “Ribavirin (RBV)” NCT01290731 ↗ “Ribavirin (RBV)” NCT01290679 ↗ “ribavirin (RBV)” NCT02399345 ↗ “Ribavirin (RBV)” NCT00991289 ↗ “Ribavirin (RBV)” NCT01581203 ↗ “Ribavirin (RBV)” NCT01732796 ↗ “Ribavirin (RBV)” NCT01023035 ↗ “ribavirin (RBV)” PMID 30598598 ↗ Nov 2018 “Ribavirin (RBV)” NCT01911845 ↗ “Ribavirin (RBV)” NCT00984620 ↗ “Ribavirin (RBV)” NCT01314261 ↗ “Ribavirin (RBV)” NCT02194998 ↗ “Ribavirin (RBV)” NCT01309932 ↗ “Ribavirin (RBV)” NCT02493855 ↗ “ribavirin (RBV)” PMID 29546644 ↗ Mar 2018 “Ribavirin (RBV)” NCT01366638 ↗ “Ribavirin (RBV)” NCT01390844 ↗ “ribavirin (RBV)” NCT02243293 ↗ “Ribavirin (RBV)” NCT01292239 ↗ “Ribavirin (RBV)” NCT01358864 ↗ “Ribavirin (RBV)” NCT01482767 ↗ “Ribavirin (RBV)” NCT01685203 ↗ “ribavirin (RBV)” NCT00947349 ↗ “Ribavirin (RBV)” NCT02105454 ↗ “ribavirin (RBV)” NCT02723084 ↗ “Ribavirin (RBV)” NCT01289782 ↗ “Ribavirin (RBV)” NCT02219490 ↗ |
| Known as | RBV: Copegus (Hoffman La-Roche) | “RBV: Copegus (Hoffman La-Roche)” NCT00977054 ↗ |
| Known as | Rebetol | “Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily...” NCT01838772 ↗14“in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight” NCT00956982 ↗ “Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol)” NCT00528528 ↗ “treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)” NCT03547895 ↗ “Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol” NCT00367887 ↗ “Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules” NCT00135798 ↗ “REBETOL is the Schering-Plough brand name for ribavirin.” NCT00081770 ↗ “Rebetol® (ribavirin), 1000/1200mg by mouth daily” NCT01949168 ↗ “Ribavirin (Rebetol)” NCT00207363 ↗ |
| Known as | REBETOL [the Schering-Plough brand name for ribavirin] | “REBETOL [the Schering-Plough brand name for ribavirin]” NCT00081770 ↗ |
| Known as | Rebetol, Schering-Plough) | “Rebetol, Schering-Plough)” NCT00556504 ↗ |
| Known as | RIB | “ribavirin (RIB) was given for 12 weeks.” NCT03499639 ↗ |
| Known as | Ribasphere | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01795911 ↗ |
| Known as | Ribavarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02204475 ↗ |
| Known as | Ribavirin (COPEGUS) | “Ribavirin (COPEGUS)” NCT01289496 ↗ |
| Known as | Ribavirin (Copegus, F. Hoffman-LaRoche) | “Ribavirin (Copegus, F. Hoffman-LaRoche)” NCT00491244 ↗ |
| Known as | Ribavirin (RBV) | “Ribavirin (RBV)” NCT01052701 ↗ |
| Known as | Ribavirin Capsules | “Drug: Ribavirin Capsules” NCT04828564 ↗ |
| Known as | Ribavirin: Rebetol | “Ribavirin: Rebetol” NCT01457937 ↗ |
| Known as | Ribavirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00199719 ↗ |
| Known as | Ro20-9963 | “A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C” NCT00144469 ↗ |
| Known as | SCH 018908 | “Ribavirin (SCH 018908)” NCT00724620 ↗1“Ribavirin (SCH 018908)” NCT00687544 ↗ |
| Known as | SCH 18908 | “PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with...” NCT00081770 ↗3“REBETOL (ribavirin; SCH 18908)” NCT00039871 ↗ “Ribavirin (SCH 18908)” NCT00910624 ↗ “Ribavirin (SCH 18908)” NCT00708500 ↗ |
| Known as | Vilona | “ribavirin [Vilona]” NCT01615393 ↗ |
| Known as | Viraferon-peg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00723242 ↗ |
| Known as | Virazole | “50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.” NCT04356677 ↗6“Virazole (Ribavirin) Inhalation Solution” NCT00031473 ↗ “Ribavirin (Virazole) Injection” NCT00992693 ↗ |
| Known as | Virazole (Ribavirin); | “Virazole (Ribavirin);” NCT02455167 ↗ |
| Action | Inhibit | “ribavirin appears to inhibit the spread of the virus” NCT00000733 ↗ |
| Modality | Small molecule | “RBV is another antiviral nucleotide analogue with few adverse effects” NCT00117533 ↗ |
| Route | Oral | “All patients take INPX capsules 4 times a day and RBV capsules 2 or 3 times a day.” NCT00000699 ↗ |
| Target | EIF4E | “Ribavirin impedes eIF4E mediated transformation in vitro, in primary human specimens and in animal models.” NCT00559091 ↗ |